Perch News App - Company Name


Bayer Receives Approval in the UK for Xarelto® (rivaroxaban) to Treat Children With Venous Thromboembolism (VTE) and to Prevent VTE Recurrence

Bayer has received approval for the use of its oral Factor Xa inhibitor Xarelto® (rivaroxaban) to treat VTE and to prevent VTE recurrence in children from birth to below 18 years after at least 5 days of initial parenteral anticoagulation treatment, including catheter related thrombosis, cerebral vein and sinus thrombosis. The use of a new formulation and strength granules for oral suspension 1mg/ml was also approved.


Three clinical trial platforms working together to test the effects of anticoagulants in people with COVID-19 have paused enrolment of critically ill hospitalised patients.

Page 1 of 11 Next